{"links":{"feed":"https://www.erudio.com/reports/topacio-nct02657889/feed.json","html":"https://www.erudio.com/reports/topacio-nct02657889","json":"https://www.erudio.com/reports/topacio-nct02657889.json","markdown":"https://www.erudio.com/reports/topacio-nct02657889.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"topacio-nct02657889"}},"request":"https://www.erudio.com/contact?report=topacio-nct02657889"},"offer":{"cited_clinicians":6,"cited_commentary_sources":30,"verified_hcp_statements":183,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":9},"for_sale":true,"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"topacio-nct02657889"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=topacio-nct02657889","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/topacio-nct02657889","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_line":"Standard · 183 verified statements · 28 from 6 confirmed clinicians","size_rule":"Standard: 151–300 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-15T20:48:19.946035Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: finding titles; the speakers each finding title counts; the limitations; the examples from the report. Finding titles on this page say which of the speakers hold each view, with no word judging benefit or harm; the report keeps its own titles."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":2},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)"},{"claim_count":16,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":9,"title":"Primary endpoint: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1"},{"claim_count":5,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":9,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":2,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":18,"coverage":"discussed","id":"A1","source_count":9,"title":"Biomarker interpretation and candidate selection measures"},{"claim_count":10,"coverage":"discussed","id":"A2","source_count":3,"title":"Guideline positioning, PARP-class caution and treatment-versus-maintenance boundaries"},{"claim_count":22,"coverage":"discussed","id":"A3","source_count":18,"title":"Early enthusiasm, evolving ORR expectations and development caution"},{"claim_count":24,"coverage":"discussed","id":"A4","source_count":2,"title":"Recurrent platinum-resistant ovarian cancer treatment selection, access and supportive care"},{"claim_count":12,"coverage":"discussed","id":"A5","source_count":3,"title":"Alternative ovarian immunotherapy regimens and the MEDIOLA comparison"},{"claim_count":23,"coverage":"discussed","id":"A6","source_count":2,"title":"Biological rationale and contextual MEDIOLA, TOPACIO and OlympiAD comparisons"},{"claim_count":30,"coverage":"discussed","id":"A7","source_count":1,"title":"Biopsy-led research, macrophage metabolism, CSF1R modulation and STING priming"}],"counts":{"beyond_population_findings":4,"beyond_population_statements":62,"cited_clinicians":6,"cited_clinicians_by_role":{"physician":1,"physician, Gynecologic oncology":1,"physician, Medical oncology":2,"physician, Surgical oncology":2},"cited_physicians":6,"cited_sources":35,"claims_by_expression_type":{"comparison":16,"experience":3,"interpretation":56,"opinion":36,"primary_context":20,"question":4,"restatement":29,"uncertainty":7,"unspecified":12},"claims_by_kind":{"objective_result":2,"protocol_statement":12,"publication_statement":29,"source_observation":140},"clinician_statements":28,"evidence_units":116,"findings":10,"organisational_accounts":7,"people_cited":18,"people_identity_verified":9,"people_total":18,"screened_sources":69,"verified_claims":183},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":3,"experience":0,"questions":1,"restated":2,"views":5},"limitations":3,"links":{"context":1,"support":15},"ma_question":true,"named_voices":3,"passages":10,"sources":5,"sources_by_kind":{"commentary":1,"media":2,"publication":2}},"title":"Niraparib plus pembrolizumab: where speakers split on what the combination adds","title_holders":{"cited_claim_ids":["claim-e966ad8d6cf3408567e2","claim-ab3f7ea0ec0e49f713d7","claim-31de43f328f6ed48bcc3","claim-2e961f3b8c0bf162094e","claim-e1b8022565ed5d3cda08","claim-d0a49bf5168055ce3853"],"clinicians":false,"holders":3,"sides":[{"cited_claim_ids":["claim-e966ad8d6cf3408567e2","claim-ab3f7ea0ec0e49f713d7","claim-31de43f328f6ed48bcc3","claim-2e961f3b8c0bf162094e"],"holders":2},{"cited_claim_ids":["claim-e1b8022565ed5d3cda08","claim-d0a49bf5168055ce3853"],"holders":1}],"speakers":3,"view":"split"},"evidence_line":"11 statements from 3 speakers in 5 sources, 2 of them podcasts or videos","holder_line":"3 of the 3 named speakers in this finding take a side on this question: 2 on one side, 1 on the other"},{"cited_clinicians":1,"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":5,"views":5},"limitations":3,"links":{"context":1,"support":12},"ma_question":true,"named_voices":2,"passages":9,"sources":3,"sources_by_kind":{"media":3}},"title":"Niraparib plus pembrolizumab: a clinician cites activity but notes no NCCN listing","title_holders":{"cited_claim_ids":["claim-29ad0929bf27a838ceea","claim-6f6ca13e5280401dab8c"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"11 statements from 2 speakers in 3 sources, all podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician"},{"cited_clinicians":4,"id":"F3","structure":{"claims":22,"claims_by_group":{"comparisons":3,"experience":1,"questions":3,"restated":8,"views":7},"limitations":3,"links":{"context":5,"support":24},"ma_question":true,"named_voices":7,"passages":19,"sources":10,"sources_by_kind":{"commentary":6,"media":3,"publication":1}},"title":"Activity beyond BRCA: most speakers see it, but some seek selection markers","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-4341167325cc2970f301","claim-6c41fa879897af502d09","claim-d0c3d21d6c14a93604e6"],"clause":"some seek selection markers","holders":2},"cited_claim_ids":["claim-31de43f328f6ed48bcc3","claim-29ad0929bf27a838ceea","claim-8259b71a3dc2568c8e82","claim-0c00e71b766933d86930","claim-32726a26244c9baa6554","claim-32b5e70e2ceff2bb3997","claim-6aedb6260c9594928d83"],"clinicians":false,"holders":6,"speakers":7,"view":"reading"},"evidence_line":"22 statements from 7 speakers in 10 sources, 3 of them podcasts or videos","holder_line":"6 of the 7 named speakers in this finding hold this view; 2 of the 7 hold its caveat, “some seek selection markers”"},{"cited_clinicians":2,"id":"F4","structure":{"claims":24,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":5,"views":15},"limitations":3,"links":{"context":1,"support":25},"ma_question":true,"named_voices":9,"passages":21,"sources":19,"sources_by_kind":{"commentary":19}},"title":"TOPACIO response data: what speakers highlight, but one notes ORR fell","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-88e4201726817d9c430b","claim-1ceb857d0dfbaa4b23e8","claim-693653dfd301bee3091f"],"clause":"one notes ORR fell","holders":1},"cited_claim_ids":["claim-e966ad8d6cf3408567e2","claim-32b5e70e2ceff2bb3997","claim-46225c20b3c3c40db379","claim-fbfa23cba822201baa3e","claim-465ef28e3f70300de4b2","claim-cd09f69cf178e98c5c42","claim-88e4201726817d9c430b","claim-2a96a844e687d46fafa8","claim-d6b96408cfb357eaab2c","claim-284df72432c5e70c7afb","claim-a0fec822a36d05bbc7c2","claim-806409b91d9b46749a44","claim-915deba05dd50c64e4d6","claim-2ac54d1b3928434e5bc2","claim-2680c106807397e1abc4","claim-2c0b82e1354252e30e01","claim-fc151fb06f4fb5050811","claim-30a0a1184dc60d1747cc","claim-693653dfd301bee3091f","claim-f1fd4a8b7924f61291a7","claim-0555ee994493774f3318","claim-129cc5e25cea6de564c5"],"clinicians":false,"holders":9,"speakers":9,"view":"reading"},"evidence_line":"24 statements from 9 speakers in 19 sources","holder_line":"9 of the 9 named speakers in this finding hold this view; 1 of the 9 holds its caveat, “one notes ORR fell”"},{"cited_clinicians":1,"id":"F5","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":3},"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":2,"passages":6,"sources":4,"sources_by_kind":{"commentary":1,"media":1,"publication":1,"registry":1}},"title":"Tolerability in breast cancer: where speakers split on which patients it covers","title_holders":{"cited_claim_ids":["claim-32726a26244c9baa6554","claim-166e1ea72a71e7acf5d6"],"clinicians":false,"holders":2,"sides":[{"cited_claim_ids":["claim-32726a26244c9baa6554"],"holders":1},{"cited_claim_ids":["claim-166e1ea72a71e7acf5d6"],"holders":1}],"speakers":2,"view":"split"},"evidence_line":"6 statements from 2 speakers in 4 sources, 1 of them a podcast or video","holder_line":"2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other"},{"cited_clinicians":1,"id":"F9","structure":{"claims":23,"claims_by_group":{"comparisons":3,"experience":1,"questions":2,"restated":5,"views":12},"limitations":3,"links":{"context":1,"support":27},"ma_question":true,"named_voices":2,"passages":11,"sources":2,"sources_by_kind":{"media":2}},"title":"PARP–immunotherapy rationale: speakers support it, but claim no clinical synergy","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-ab3f7ea0ec0e49f713d7","claim-2e961f3b8c0bf162094e","claim-ee8f61b585869496d10d","claim-251c7d7c0f70b9453b03","claim-0bef25da2eba30cdcb06"],"clause":"claim no clinical synergy","holders":2},"cited_claim_ids":["claim-1ee04f1c3299eed8f9e0","claim-c19a741810743c6c0a22","claim-a2866664010cb0b01396","claim-0486dabf3b86e0654697","claim-0d80a0b41af5a22d3d5b","claim-0f5c0389e6db1d4c7da9","claim-c3647cc26a7d12325970","claim-3b70bc92d496bae6f41b","claim-eb9df3f0d87469b02587"],"clinicians":false,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"23 statements from 2 speakers in 2 sources, all podcasts or videos","holder_line":"2 of the 2 named speakers in this finding hold this view; 2 of them hold its caveat, “claim no clinical synergy”"},{"cited_clinicians":1,"id":"F6","population":"beyond","structure":{"claims":24,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":12,"views":12},"limitations":5,"links":{"context":2,"support":25},"ma_question":true,"named_voices":2,"passages":10,"sources":2,"sources_by_kind":{"media":2}},"title":"Platinum resistance: how speakers weigh therapy, supportive care and when to stop","title_holders":{"cited_claim_ids":["claim-0d6ab3f232083c266340","claim-2d19f88259a31908c3b4","claim-d469b571d561862cccf3","claim-71ddd0726de1c3cd2831","claim-3c34d3bea9088fee0a46","claim-8e42e072f3807fd996cd","claim-5025826adf510c26291c","claim-22870039baad8058245a","claim-1cdb41179c2cb7b6837b","claim-4d9773122efb1b63112d","claim-4c91b45023f66c597791"],"clinicians":false,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"24 statements from 2 speakers in 2 sources, all podcasts or videos","holder_line":"2 of the 2 named speakers in this finding hold this view"},{"cited_clinicians":1,"id":"F7","population":"beyond","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":5,"views":4},"limitations":4,"links":{"context":1,"support":16},"ma_question":true,"named_voices":1,"passages":8,"sources":2,"sources_by_kind":{"media":2}},"title":"Platinum resistance: why a clinician favors immunochemotherapy over PD-1 drugs alone","title_holders":{"cited_claim_ids":["claim-1fd0926d793d81897859","claim-9df8cee1f961049ee43d","claim-83495a8cc1f7c70f8e78"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"11 statements from 1 speaker in 2 sources, all podcasts or videos","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":0,"id":"F8","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":0,"views":0},"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"media":1}},"title":"MEDIOLA triplet: a speaker favors it, but leaves its advantage open","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-bd8202c21987aa23cf8d"],"clause":"leave its advantage open","holders":1},"cited_claim_ids":["claim-f1f53a8e0ce42d50b398"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view; 1 of them holds its caveat, “leave its advantage open”"},{"cited_clinicians":0,"id":"F10","population":"beyond","structure":{"claims":30,"claims_by_group":{"comparisons":1,"experience":2,"questions":2,"restated":7,"views":18},"limitations":4,"links":{"context":0,"support":32},"ma_question":true,"named_voices":1,"passages":15,"sources":1,"sources_by_kind":{"media":1}},"title":"PARP combinations: a speaker looks to biopsies, macrophages and priming","title_holders":{"cited_claim_ids":["claim-42bdb63ac73c500fa18a","claim-a960ee785f6640c2da58","claim-9204685274ebdd01a51c","claim-983a03e36c6f2b78e3c8","claim-10df71524850031e8f2e","claim-7ce10acec115ab888a27","claim-8ce1808476255d0679cc"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"30 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view"}],"open_question":{"basis":"From finding F1 (11 statements from 3 speakers in 5 sources)","cited_claim_ids":["claim-e966ad8d6cf3408567e2","claim-ab3f7ea0ec0e49f713d7","claim-30f94c128a1a21271f76","claim-31de43f328f6ed48bcc3","claim-2e961f3b8c0bf162094e","claim-e1b8022565ed5d3cda08","claim-07186ce387f8d6e1be8c","claim-d0a49bf5168055ce3853","claim-55de33eb13d1a2b9d414","claim-23b3810a2cf13ad2a5e2"],"finding_ids":["F1"],"question":"What do clinicians need to see in response rates and duration to determine whether niraparib plus pembrolizumab adds benefit over PARP inhibitor monotherapy in advanced triple-negative breast cancer or recurrent ovarian cancer?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers question added benefit; one interview reads possible synergy"},{"id":"section-2","level":2,"title":"One episode distinguishes activity from clinical positioning"},{"id":"section-3","level":2,"title":"Speakers leave biomarker-based selection unsettled"},{"id":"section-4","level":2,"title":"X accounts combine early enthusiasm with concern about the evolving signal"},{"id":"section-5","level":2,"title":"One account and one presentation offer qualified safety reassurance"},{"id":"section-6","level":2,"title":"Speakers distinguish mechanistic rationale from demonstrated clinical benefit"},{"id":"section-7","level":2,"title":"Beyond the trial population"},{"id":"section-8","level":3,"title":"Speakers include reassessment, access and supportive care in treatment choice"},{"id":"section-9","level":3,"title":"One episode favors alternative immunochemotherapy strategies"},{"id":"section-10","level":3,"title":"One speaker favors the MEDIOLA triplet but leaves its apparent advantage unresolved"},{"id":"section-11","level":3,"title":"One presentation proposes biopsy-led development and additional immune targeting"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase1, phase2","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":6}],"id":"T2","label":"Primary endpoint: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":3},{"id":"F9","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":6},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T6","label":"Safety and tolerability"},{"findings":[],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-15T20:48:19.946035Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-15T21:57:05Z","record_hash":"3778f252bc4448008b25aa09714061dcdeddf9030bd667ada9731c4a1c8da818","release_hash":"eea71a38121b4281d3ed59a1393baff4f50037099b6329691ef4760e1de6290b","report_id":"erudio-nct02657889","run_id":"aa91a560-3794-4447-afc6-d16c964e6e33","schema_version":"5.0","slug":"topacio-nct02657889","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A surgical oncologist reads TOPACIO as suggesting the drugs work better together, citing BRCA-wild-type ovarian responses. Another speaker finds the drugs’ contributions difficult to separate in TNBC; a speaker described in the sources as involved in the trial sees TNBC responses as similar to PARP monotherapy. The ovarian and TNBC observations are not directly matched. Genomic and immune markers still need validation before they can guide treatment selection.","examples":[{"claim_id":"claim-32726a26244c9baa6554","finding_id":"F3","identity_check":"npi_registry","month":"2018-06","region":"US","role":"Physician","source_type":"x_thread","statement":"describes great activity and a good toxicity profile for niraparib plus pembrolizumab in TOPACIO TNBC, extending beyond BRCA mutation and PD-L1 expression."}],"meta_description":"69 sources screened · 183 verified statements (28 from clinicians verified by NPI or staff page) from 35 sources · 10 findings. Updated Nov 15, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-15T21:57:05Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-15T21:57:05Z","kind":"routine","summary":"The trial's name is spelled as its investigators write it, “TOPACIO” (NCT02657889), outside quotations (was “Topacio”, “Topazio”)."},{"affected_ids":[],"date":"2026-11-15T21:57:05Z","kind":"routine","summary":"An editorial bracket follows a transcription-garbled trial name in quotations: “Topazio [TOPACIO]”."},{"affected_ids":[],"date":"2026-11-15T21:57:05Z","kind":"routine","summary":"Other trials' names are spelled as their investigators write them, outside quotations: “MEDIOLA” (was “Madiola”), “KEYLYNK” (was “KEYLINK”)."},{"affected_ids":[],"date":"2026-11-17T00:18:24Z","kind":"routine","summary":"Corrected to match the delivered report: finding titles; the speakers each finding title counts; the limitations; the examples from the report. Finding titles on this page say which of the speakers hold each view, with no word judging benefit or harm; the report keeps its own titles."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":69},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Not yet captured in this edition: a view on checkpoint-combination benefit–risk and exploratory patient selection in recurrent ovarian cancer; a view on checkpoint inhibitor monotherapy versus chemotherapy as context for combination treatment in recurrent ovarian cancer; a view on mirvetuximab as an alternative for platinum-resistant ovarian cancer, including patient selection, efficacy and toxicity; a view on checkpoint-inhibitor combination selection, toxicity and exploratory subgroups in recurrent ovarian cancer; a view on molecular profiling and mutation-selected trial options for recurrent platinum-resistant ovarian cancer.","Discussion that does not name the trial may be missing from this edition.","2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.","175 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 24 sources about other trials or topics are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion; no prevalence, consensus or adoption rate can be inferred.","Several X accounts are organizational, anonymous or lack established clinical roles. Relays and reposts do not demonstrate independent clinical endorsement.","Unidentified speech remains unnamed even when the recording includes named participants; it may belong to a participant already discussed.","Commentary spans different years, cohorts, treatment settings and stages of data maturity. Differences do not by themselves demonstrate that a speaker changed position.","Descriptions of approvals, guidance and treatment practice remain attributed to the time and source that expressed them, including the updated episode dated July 21, 2026.","The complete 2019 TNBC and ovarian results articles were unavailable. Available article summaries and the ovarian correlative publication support only the context they contain.","Important alternative-treatment assessments remain incomplete: mirvetuximab regimens, bevacizumab selection, checkpoint doublets, pazopanib and cytotoxic choices tailored to neuropathy or access burdens. The report is therefore not a complete treatment pathway or comparison of alternatives.","Some connected discussion of comparator interpretation and constraints on further development is not fully characterized, limiting conclusions about why particular alternatives were favored or pursued.","Some alternative PARP-combination discussion was incomplete or had unclear drug names and prior-PARP eligibility wording, limiting assessment of those strategies.","The single-arm design and cross-study comparisons do not establish the combination's incremental efficacy or a treatment-predictive biomarker.","The ovarian biomarker work is exploratory, with incomplete tissue availability and a need for independent validation; laboratory and mouse findings are not clinical treatment evidence."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":3,"publication":3,"registry":2,"regulatory":0,"x_thread":24,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":30,"context":2,"methods":2,"results":1},"count":35,"evidence_window":{"end":"2026-07-21","start":"2017-04-20"},"retrieval_snapshot":"2026-11-15T17:59:51.561939Z","timeline":[{"count":1,"week":"2017-W16"},{"count":1,"week":"2017-W36"},{"count":1,"week":"2017-W37"},{"count":1,"week":"2017-W51"},{"count":5,"week":"2018-W13"},{"count":1,"week":"2018-W20"},{"count":1,"week":"2018-W21"},{"count":8,"week":"2018-W22"},{"count":2,"week":"2018-W23"},{"count":1,"week":"2018-W27"},{"count":1,"week":"2018-W40"},{"count":1,"week":"2019-W30"},{"count":1,"week":"2019-W43"},{"count":1,"week":"2022-W49"},{"count":1,"week":"2023-W06"},{"count":1,"week":"2023-W22"},{"count":1,"week":"2024-W30"},{"count":1,"week":"2026-W30"}],"undated_sources":5},"quote_policies":[{"id":"clinicaltrials:NCT02657889:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02657889:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02657889:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02657889:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02657889:sap:2","quote_policy":"short_quote_link_out"},{"id":"pubmed:31194225","quote_policy":"short_quote_link_out"},{"id":"pubmed:31194228","quote_policy":"short_quote_link_out"},{"id":"pubmed:32193378","quote_policy":"short_quote_link_out"},{"id":"openfda:b7f675e2-159c-490c-b6f4-3f16d9492b7d:20260728","quote_policy":"short_quote_link_out"},{"id":"openfda:9333c79b-d487-4538-a9f0-71b91a02b287:20261016","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zupo6ieja7q6w7ylmmwdmbk4-3lckfjqxcic2j","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:1104cf","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a9df94","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ecd95c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1001138261975224320:971c32e8-50c1-4341-a920-76ce9441069f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1001138375955570693:ba483d00-641f-40dd-8954-4e65d8f19261","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1001139189814124545:0c270c03-6436-4b5e-aee7-91b98662d619","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1001561854815195137:9e8d2d13-1240-4afc-9dd8-3b45dcffd11e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1002390933378236421:4c2067b5-ece7-4b73-bab5-9d05590f5004","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003300450718896130:ea3a9e27-79e6-40a4-94d0-5a43958e1d8e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003304922526507013:a48d643a-58ba-4eec-b2ff-72bbcef3252e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003305660493254657:3f4d9c13-e884-461a-a587-cfacb9f4d15d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003308204971917312:3baaf05c-7607-4491-bfd0-ce6c3475ef1d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003309085490667520:2d7f1ba4-af8e-4da2-b706-046e889c8849","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003309366697693185:c0b52f12-eddc-4969-94a2-1e5887244737","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003311253576732672:264e431a-c833-42e3-8806-dea0c6f88df0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003315555531706371:92ec8393-5281-49a3-b550-7ef736b2cac0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003376855712501760:9dde6013-09f8-40d8-bb47-636cbe44788a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003742577294741505:dbac3feb-1104-4aef-8c15-3914332c8305","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003745628139151360:331b3b5f-7035-4701-ad49-c8595afd4064","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003749825957986305:9b1f821e-8217-496f-88ac-f8d7d3e7ae3f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003848965337513984:280b5687-eb74-48a5-94c6-6d867c8abcd0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1003944166169116672:6355ecd6-2750-4331-91bd-836614e77c44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1022602555627646976:a7cd9c6f-e190-4945-8d7b-f49c2c319677","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1037417857687027712:6e6e0bbf-982c-44c0-8df0-1e8f7c18ca8f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1037924691028193280:88898f75-8f29-42b9-a6fd-e3b32065947a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1047912680940621824:94fb7864-4725-4e64-9bf3-f53e1e4d9b4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1101887935308226561:a609f3da-b84e-4e45-bf93-6b3440885b3b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1135173371040292865:14ba6da2-adb3-40e8-95bc-3ab5f4d8473c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1149095706608750592:8b352edc-9f88-41e9-aa2d-62feed89e366","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1151627892029349890:c641f96f-d67d-478d-958a-038a59565bbf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1154903731001057281:ec0a17fd-2b98-4e51-8f05-cbfc2ef10fd3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1188399861235933184:208d904d-6afe-41cf-ab03-1378a9355f6e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1210062706319011840:fe8f4f80-3408-40ff-be70-d2f17dc79b8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1235973221884653568:1dd98010-5663-4e56-b516-15b25c3f73b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1362534741405175814:40a2dbd9-e677-4a5e-ae5e-44da5d68d1fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1401592789780111368:8ee054cf-5f1b-4edb-8c9a-6873c9f525e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2004710030168522989:ffb7d814-9993-4b6f-bfa9-63ef85489a81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:855074852885209088:82e93abb-81ef-4211-a18d-8f78840a0dd1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:871354836368990208:4412d16e-3187-46af-8b91-629ea1aae6ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:885804725555392512:c8b46c55-6bf6-407e-ac32-6ee97297062e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:895020530486693888:41d5cc77-f793-4750-ad16-2135bef9fedd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:903049697631326208:9fadb75f-6254-4072-873f-1f40ecba5802","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:906206018362896385:5b3db75b-0c17-4fab-9012-2004f59b9c2c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:907169052216438784:143d2eaa-37fb-41c5-878d-8436c36b2b5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:928245411881594880:2196f04a-3bc2-4ecb-98fd-60277b9e07ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:943105000015835137:6cf87f14-6393-41fa-b91e-4c9d1e005328","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:970147172162424832:c9d313de-4c20-4271-b0e0-0c68bc5678da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978361070652928002:0145ff06-be38-46a8-9e18-e196c6032eef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978361501957410816:2e5b3692-328c-4eee-95eb-b029aba78370","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978361630101790720:8ffd4b61-658f-45cc-9151-c5d566b9856b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978361773584732162:1a1bfdba-0cc7-41e7-817b-ffe460635db3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978361830077878272:c3e6fc09-c696-4c4d-b21b-2c1cbc0bfd64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978362831950286848:1e7c7d41-9cff-4b88-a3e0-c0bc14250c3a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978362844508053510:9df3f482-466d-4443-bb7b-4247de2e37bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978363825236869121:d03a859d-6047-40ce-89e1-618f07ce6b95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978381165534072832:06ef3a24-78a8-4940-b62d-b7127c863e41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978394915926347776:cf714a74-1ab9-4fed-97a8-1557d80f0ddd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978403486768517120:91711932-d730-4d99-a3af-31690b32fb55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978412305141633026:11fa71f3-8078-485d-afe9-579fa3fe922c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978454121404547072:aef0446b-dead-4667-925e-e3ffe032d2e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978558853100003328:5f81c29a-88f3-43e4-9ed2-0f28fad2d83d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:978606099535364096:411b894c-d3e6-48ed-8704-35d9db9b93e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:979407680031903746:9cc28791-41e6-4b5c-9a32-a61aedb567a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:996897999044448261:45f0b272-44c4-4de3-87c8-ab0d257ace85","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:998920869912211463:5728a81d-e4ea-4784-8d8f-e5ad4883dc3f","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4R87TrbuhAc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ZWAhFzb2FWM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:v98wsVKxXCc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":62,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":69},"count":69,"evidence_window":{"end":"2026-07-21","start":"2017-04-20"},"retrieval_snapshot":"2026-11-15T17:59:51.561939Z","timeline":[{"count":1,"week":"2017-W16"},{"count":1,"week":"2017-W22"},{"count":1,"week":"2017-W28"},{"count":1,"week":"2017-W32"},{"count":1,"week":"2017-W35"},{"count":1,"week":"2017-W36"},{"count":1,"week":"2017-W37"},{"count":1,"week":"2017-W45"},{"count":1,"week":"2017-W51"},{"count":1,"week":"2018-W09"},{"count":16,"week":"2018-W13"},{"count":1,"week":"2018-W20"},{"count":1,"week":"2018-W21"},{"count":14,"week":"2018-W22"},{"count":5,"week":"2018-W23"},{"count":1,"week":"2018-W27"},{"count":1,"week":"2018-W30"},{"count":2,"week":"2018-W36"},{"count":1,"week":"2018-W40"},{"count":1,"week":"2019-W09"},{"count":1,"week":"2019-W22"},{"count":1,"week":"2019-W28"},{"count":1,"week":"2019-W29"},{"count":1,"week":"2019-W30"},{"count":1,"week":"2019-W43"},{"count":1,"week":"2019-W52"},{"count":1,"week":"2020-W10"},{"count":1,"week":"2021-W07"},{"count":1,"week":"2021-W22"},{"count":1,"week":"2022-W49"},{"count":1,"week":"2023-W06"},{"count":1,"week":"2023-W22"},{"count":1,"week":"2024-W30"},{"count":1,"week":"2024-W49"},{"count":1,"week":"2025-W52"},{"count":1,"week":"2026-W30"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":47,"publication":34,"registry":10,"regulatory":0,"x_thread":30,"x_video":0,"youtube":62}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: niraparib","status":"unmapped"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"}],"indications":[{"reason":"Unmapped registry condition: Neoplasms","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Triple-negative breast cancer","slug":"triple-negative-breast-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Ovarian cancer","slug":"ovarian-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"},{"reason":"Unmapped registry condition: Stage IV Breast Cancer","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Fallopian tube cancer","slug":"fallopian-tube-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Primary peritoneal cancer","slug":"primary-peritoneal-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"TOPACIO","aliases":["TOPACIO","Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer","Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer"],"brief_title":"Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer","collaborators":["Merck Sharp & Dohme LLC"],"conditions":["Neoplasms","Triple Negative Breast Cancer","Ovarian Cancer","Breast Cancer","Metastatic Breast Cancer","Advanced Breast Cancer","Stage IV Breast Cancer","Fallopian Tube Cancer","Peritoneal Cancer"],"display_condition":"advanced triple-negative breast cancer or recurrent ovarian cancer","display_interventions":[["niraparib","pembrolizumab"]],"enrollment":{"count":122,"type":"ACTUAL"},"interventions":[{"name":"niraparib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"}],"nct_id":"NCT02657889","official_title":"Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer","overall_status":"COMPLETED","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2018-05-14","type":"ACTUAL"},"primary_endpoints":[{"description":"DLTs are defined as: Any treatment-related Grade \\>=3 non-hematologic clinical (non-laboratory) adverse event (AE); Any treatment-related Grade 3 or Grade 4 non-hematologic laboratory (lab) abnormality if Medical intervention is required to treat the participant or the abnormality leads to hospitalization or the abnormality persists for \\>=7 days; Any treatment-related hematologic toxicity specifically defined as: Thrombocytopenia Grade 4 for \\>=7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion, Neutropenia Grade 4 for \\>=7 days, or Grade 3 or 4 associated with infection or febrile neutropenia, Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion; Any treatment-related AE leading to niraparib dose interruption per the following criteria: A dose interruption for a non-DLT lab abnormality lasting \\>=14 days, A dose in interruption per dose modification rules for non-hematologic AE leading to \\<80 percent (%) of an intended dose being administered.","measure":"Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)","timeFrame":"During Cycle 1, ie, during the first 21 days of treatment"},{"description":"ORR is defined as the percentage of participants with a confirmed best overall response of Complete Response (CR) or Partial Response (PR), RECIST v1.1 for target lesions as assessed by the Investigator. CR is defined as disappearance of all target lesions, Any pathological lymph nodes must be \\<10 millimeters (mm) in the short axis; PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters.","measure":"Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1","timeFrame":"Up to 40 weeks"}],"registered_date":{"date":"2016-01-18","type":"ESTIMATED"},"registry_last_updated":"2022-12-01","registry_url":"https://clinicaltrials.gov/study/NCT02657889","short_name":"TOPACIO","short_name_basis":"registry_acronym","sponsor":"Tesaro, Inc.","start_date":{"date":"2016-04-15","type":"ACTUAL"},"study_design":"interventional, na, single group, phase1, phase2","study_ids":[{"id":"213363","type":"sponsor_study_id"},{"domain":"Tesaro","id":"3000-PN162-01-001","type":"other"}],"study_type":"INTERVENTIONAL"}}}